Spark Therapeutics, Inc. (NASDAQ:ONCE)

CAPS Rating: 4 out of 5

Caps

How do you think ONCE will perform against the market?

Add Stock to CAPS Watchlist

All Players

61 Outperform
4 Underperform
 

All-Star Players

28 Outperform
0 Underperform
 

Wall Street

1 Outperform
0 Underperform
 

Top ONCE Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

SaintCroix (99.06)
Submitted December 23, 2017

The FDA has just approved their drug for a rare form of blindness. It's the first gene therapy for a genetic disease in human history. The price the company is talking about charging for this drug is $1 million dollars. And the reason they are… More

TSIF (99.98)
Submitted October 05, 2015

WARNING: BIOPHARMS on "news", (testing results, approvals) can overshoot, drop and climb much higher as shorts / speculators jockey with day traders to open and close positions... my thumbing is based on past patterns and the only rule I have about… More

ONCE VS S&P 500 (SPY)

ONCE Summary

Fools bullish on ONCE are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about ONCE.

Recs

0
Member Avatar TMFBigFrog (94.20) Submitted: 6/2/2018 10:46:49 AM : Outperform Start Price: $80.78 ONCE Score: -35.98

One recent approval and the potential for more. The adeno-associated virus vector it uses has shown success and looks promising for future therapies.

Recs

0
Member Avatar TMFTypeoh (91.50) Submitted: 5/31/2018 9:45:27 AM : Outperform Start Price: $78.52 ONCE Score: -32.47

Through the FDA with one drug and more on the way

Recs

1
Member Avatar SaintCroix (99.06) Submitted: 12/22/2017 9:44:01 PM : Outperform Start Price: $52.87 ONCE Score: -1.94

The FDA has just approved their drug for a rare form of blindness. It's the first gene therapy for a genetic disease in human history.

The price the company is talking about charging for this drug is $1 million dollars. And the reason they are charging so much is that it's a one-and-done drug. You have one injection and you are cured.

There are currently 1,000-3,000 patients in the U.S. with this disease. So, for a million dollar price tag, that would be a $1-$3 billion market. (Assuming all the people with the disease have health insurance).

The conservative number I have seen is $600,000 for the drug, which works out to $600 million to $1.3 billion.

There's no recurring revenue. Once the patient is treated they are no longer a patient. They've been tracking patients from the first clinical trials for 4 years and so far they are still cured.

Also those numbers are just for the U.S.

Current price is $52 a share. Stock is 40% off its highs. Market cap is just under $2 billion. They have multiple drugs in their pipeline, including a cure for both forms of hemophilia.

There was an article in Forbes that was raving about Roche's new clotting treatment for hemophilia, and how big that market is. But that market's going to be wiped out! We have a cure for hemophilia on the way! It's a one-time treatment. One and done. Bully!

Leaderboard

Find the members with the highest scoring picks in ONCE.

Score Leader

clangmead

clangmead (58.02) Score: +99.04

The Score Leader is the player with the highest score across all their picks in ONCE.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
paullng < 20 2/10/2016 Outperform 3Y $22.61 +150.46% +56.23% +94.24 0 Comment
portefeuille 98.53 2/10/2016 Outperform 5Y $23.30 +143.05% +55.12% +87.93 0 Comment
GreenAB 40.43 3/20/2015 Underperform NS $71.01 -20.25% +38.71% +58.96 0 Comment
dollarsandcents1 < 20 4/6/2016 Outperform 5Y $32.29 +75.38% +42.55% +32.83 0 Comment
freneyjohn < 20 2/23/2015 Underperform 1Y $52.50 +7.87% +38.06% +30.19 0 Comment
jeepdrew222 88.18 5/16/2016 Outperform 5Y $33.77 +67.69% +42.09% +25.61 0 Comment
rassibey86 < 20 12/11/2017 Outperform 5Y $42.97 +31.79% +9.63% +22.16 0 Comment
tortuga94 71.29 12/11/2017 Outperform 5Y $46.37 +22.13% +9.52% +12.60 0 Comment
IamaFOOL2 81.60 12/18/2017 Outperform 5Y $47.02 +20.44% +8.62% +11.81 0 Comment
Dima 91.56 1/16/2018 Outperform 5Y $49.79 +13.74% +4.50% +9.24 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackJimCramer 85.81 9/8/2016 Outperform 3W $59.90 -5.46% +33.28% -38.73 0 Comment
TrackJimCramer 85.81 9/28/2015 Underperform 3W $42.54 +40.81% +16.28% -24.52 9/8/2016 @ $59.90 0 Comment
TrackJimCramer 85.81 7/22/2015 Outperform 3W $67.15 -36.65% -11.07% -25.58 9/28/2015 @ $42.54 0 Comment

Featured Broker Partners


Advertisement